Amgen's Repatha meets mark in CVOT

Hypercholesterolemia treatment Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN) met the primary endpoint of the Phase III FOURIER cardiovascular outcomes trial by significantly reducing the risk of major cardiovascular

Read the full 288 word article

User Sign In